Home › Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
 

Keywords :   


Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy

2015-12-02 02:15:49| drugdiscoveryonline Home Page

Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, recently announced a collaboration to explore the potential utility of daily physiological activity monitoring in boys affected by Duchenne muscular dystrophy (DMD) with ActiGraph, a leading provider of objective physical activity and sleep/wake measurement solutions for the global scientific community

Tags: with daily activity trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Who is Paula Vennells? Ex-Post Office boss in Horizon IT inquiry
16.05BASF Expands Biomass Balance Portfolio for Selected Chemical Intermediates
16.05INDA Releases 11th Annual North America Supply Report
16.05Dow and SCGC Partner to Change 200KTA of Plastic Waste Into Circular Products
16.05Leanpath Uses Generative AI to Drive Action on Food Waste Data
16.05AkzoNobels Como Site Achieves Highest Automotive Industry Quality Certification
16.05ECONWARDs Counterplan for Landfill-Bound Organics
16.05Mortgage rates cut but borrowing pressures remain
More »